EUCTR2005-000730-20-ES进行中（未招募）不适用
Ensayo de fase III b, abierto, aleatorizado, de grupos paralelos, internacional y multicéntrico, para investigar los cambios en la densidad mineral ósea (DMO) de columna lumbar en mujeres posmenopáusicas con osteoporosis primaria tratadas inicialmente durante 12 meses con hormona paratiroidea de cadena completa [PTH (1-84)], seguidos por 12 meses de tratamiento con risedronato, seguidos, a su vez, por 12 meses de tratamiento con PTH (1-84) o con risedronato - Sequential treatment of postmenopausal women with primary osteoporosis
ycomed Danmark Aps0 个研究点目标入组 390 人开始时间: 2006年1月18日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 390
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Has the subject given informed consent according to local requirements before any trial related activities? (A trial related activity is any procedure that would not have been performed during the routine management of the subject).
- •2. Is the subject above 50 years old?
- •3. Is the subject postmenopausal (more than 5 years) – in the judgement of the investigator?
- •4. Does the subject have primary osteoporosis with a lumbar spine T score equal to or less than -3.0 SD (at lumbar spine L1-L4, with a minimum of two evaluable vertebrae)?
- •5. Does the subject have a life expectancy of >3 years?
- •6. Is the subject able to self-inject PTH (1-84), (or to have PTH (1-84) injection by a helper)?
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Is the subject currently in treatment with Selective Estrogen Receptor Modulators (SERMs) (e.g. raloxifen)? If the SERM treatment is terminated the subject can still be evaluated for eligibility.
- •2. Has the subject ever been treated with any bisphosphonate other than alendronate or risedronate?
- •3. Has the subject been treated with alendronate or risedronate for more than 3 years in total?
- •4. Has the subject during lifetime been treated with both alendronate and risedronate, including sequential treatment?
- •5. Has the subject during lifetime been treated with strontium > 3 months in total?
- •6. Has the subject during lifetime been treated with fluoride > 3 months in total?
- •7. Has the subject during lifetime been treated with teriparatide or PTH (1-84)?
- •8. Has the subject during lifetime been treated with calcitonin during the last 3 months?
- •9. Is the subject currently receiving antiepileptic medication?
- •10. Does the subject take any other medication, that according to investigator’s opinion, is known to affect bone metabolism?
- •11. Has the subject received or is the subject currently receiving chronic glucocorticosteroid treatment? Defined as more or equal to:
- •5.0mg prednisolon or equivalent daily for 3 months during the last year or
- •2.5mg prednisolon or equivalent daily for 6 months during the last year
- •12. Has the subject ever received radiation therapy to the skeleton?
- •13. Has the subject been treated for cancer (other than basocellular skin cancer) within the last 5 years?
- •14. Has the subject ever had malignant disease affecting the skeleton?
- •15. Has the subject ever had breast cancer?
- •16. Does the subject have any known clinically significant diseases affecting calcium metabolism?
- •17. Does the subject have any known history of metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism, Paget’s disease, osteogenesis imperfecta, or osteomalacia)?
- •18. Does the subject have a medical history of abnormalities in oesophagus prohibiting emptying of oesophagus (e.g. achalasia or stricture) and inability to ingest risedronate (should be able to take risedronate upright) judged by the investigator to be significant?
- •19. Does the subject have any known history of hypersensitivity to parathyroid hormone or risedronate or any of the excipients in the products?
- •20. Does the subject have any clinically significant conduction abnormalities e.g. second degree atrial ventricular block as assessed by the investigator based on ECG reading?
- •21. Does the subject have a plasma 25-hydroxyvitamin D level <9.2ng/ml after at least 14 days of calcium and vitamin D supplementation?
- •22. Does the subject have a plasma PTH of > 65pg/ml and a total serum calcium value >2.49 mmol/l?
- •23. Does the subject have hypercalcaemia (total serum calcium value >2.55mmol/l) after at least 14 days of calcium supplementation?
- •24. Does the subject have a clinically significant elevation of serum alkaline phosphatase judged by the investigator?
- •25. Does the subject have impaired kidney function with creatinine clearance <30ml/min (indirect measurement by serum creatinine)?
- •26. Does the subject have a 24 hours urinary calcium > 360mg after at least 14 days of calcium supplementation?
- •27. Has the subject ever shown intolerance to any bisphosphonate?
- •28. Is the subject scheduled for vertebroplasty?
- •29. Has the subject participated in a clinical trial with an Investigational Medicinal Product (IMP) during the last 30 days
研究者
相似试验
进行中（未招募）
不适用
Estudio fase III b, aleatorizado, abierto, para evaluar la viabilidad de primovacunación con una dosis única de la vacuna conjugada contra el meningococo del grupo C (NeisVac-C) en lactantes.A phase IIIB, randomized, open label, feasibility study of a single priming dose of meningococcal group c conjugate vaccine (NeisVac-C) in infants.Inmunización activa para la prevención de la enfermedad meningocócica invasiva causada por Neisseria meningitidis del serogrupo CMedDRA version: 13Level: LLTClassification code 10028911Term: Infección por Neisseria meningitidis NEOMEUCTR2010-019383-36-ESBaxter Innovations GmbH948
进行中（未招募）
1 期
Ensayo en fase III, abierto, aleatorizado, con control activo que compara el ferumoxitol con la sacarosa férrica para el tratamiento de la anemia por deficiencia de hierroA Phase III, Randomized, Open-label, Active-Controlled Trial Comparing Ferumoxytol with Iron Sucrose for the Treatment of Iron Deficiency AnemiaAnemia por deficiencia de hierroMedDRA version: 13Level: LLTClassification code 10022975Term: Anemia por déficit de hierro secundario a la pérdida (crónica) de sangreMedDRA version: 13Level: LLTClassification code 10022976Term: Anemia por déficit de hierro secundario a su ingestión inadecuada en la dietaEUCTR2010-018961-50-ESAMAG Pharmaceuticals, Inc.605
进行中（未招募）
不适用
Estudio de fase 3b, aleatorizado y abierto de bevacizumab (Avastin®) + temsirolimus (Torisel®) frente a bevacizumab (Avastin®) + interferón alfa (Roferon®) como tratamiento de primera línea en pacientes con carcinoma de células renales avanzadoPhase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin®) + Temsirolimus(Torisel®) vs. Bevacizumab (Avastin®) + Interferon-Alfa (Roferon®) as First-LineTreatment in Subjects With Advanced Renal Cell CarcinomaEUCTR2007-003793-26-ESWyeth Research Division of Wyeth Pharmaceuticals Inc.800
进行中（未招募）
1 期
n ensayo de fase III aleatorizado, abierto y multinacional que compara Amrubicina con Topotecán en pacientes con cáncer microcítico pulmonar diseminado o limitado y sensible o resistente al tratamiento, tras fracaso con quimioterapia de primera líneaA Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line ChemotherapyExtensive or limited and sensitive or refractory SCLC after failure of first-linechemotherapy. Pacientes con cáncer de pulmón microcítico (CPM) diseminado o limitado y sensible o refractario tras el fracaso de la quimioterapia de primera línea.MedDRA version: 9.1Level: LLTClassification code 10041071Term: Small cell lung cancer stage unspecifiedEUCTR2007-003989-18-ESPharmion Corporation480
进行中（未招募）
1 期
Estudio en fase 3B, aleatorizado y abierto para evaluar la seguridad y la eficacia de una pauta con un solo comprimido de emtricitabina/rilpivirina/tenofovir disoproxil fumarato en comparación con una pauta con un solo comprimido de efavirenz/emtricitabina/tenofovir disoproxil fumarato en adultos infectados por el VIH-1 que no han recibido tratamiento antirretroviral.A Phase 3B, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil FumarateCompared with a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.Infección por el VIH-1Human Immunodeficiency Virus (Type 1) InfectionMedDRA version: 12.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2010-024007-27-ESGilead Sciences, Inc.799